The research study was designed to compare the safety and efficacy of the regimen of 5-flurouracil with cisplatin of investigational armwith the reference regimen of gemcitabine with cisplatin for the treatment of gallbladder cancer.Atotal of 60 patients were enrolled in the study.Out of 30 patients enrolledinarm-A (Gemcitabine withCisplatin) and 30 patients enrolledin arm-B (5-Flurouracilwith Cisplatin) for safety assessment. For the efficacy evaluation total of 16 patients enrolled which is equally divided in both arm.Total 150 cycles of chemotherapy were given to each arm of patients. Both armswere well balanced with respect to age, stage of disease and measurability.The overall response rate (ORR) was 62.5% in arm-A compared to 50% in arm-B (p = 0.34). Whereas 95% confidence interval (CI) for the efficacy was found 46.25-8.74%32.67-67.32% between arm-A and arm-B.The most prevalent toxicities were found anemia (p < 0.05), neutropenia (p < 0.05) leucopenia (p<0.05) and thrombocytopenia (p < 0.05) and it occurred at a higher rate in arm-B than in arm-A of various grades.There was no statistically significant efficacy & toxicity for gemcitabine and cisplatin with 5-flurouracil and cisplatin however there was an overall more benefit in arm-A patients than arm-B patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603890 | PMC |
Br J Hosp Med (Lond)
January 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
The relationship between retinal fundus hemorrhage and the severity of coronary artery lesions remains unclear. This study aimed to explore the incidence of fundus hemorrhage in patients at high risk of coronary heart disease (CHD) and to examine its correlation with the SYNTAX score, a tool used to assess the complexity of coronary artery disease. This retrospective study consecutively enrolled patients undergoing coronary angiography (CAG) at Beijing Anzhen Hospital Hospital from June 2019 to January 2020.
View Article and Find Full Text PDFStat Med
February 2025
U.S. Food and Drug Administration, Silver Spring, Maryland.
The recent U.S. Food and Drug Administration guidance on complex innovative trial designs acknowledges the use of Bayesian strategies to incorporate historical information based on clinical expertise and data similarity.
View Article and Find Full Text PDFCancer Med
February 2025
Pulmonology and Thoracic Oncology Department, APHP Hôpital Tenon and Sorbonne Université, Paris, France.
Background: Real-world data regarding patients with non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations receiving mobocertinib are limited. This study describes these patients' characteristics and outcomes.
Methods: A chart review was conducted across three countries (Canada, France, and Hong Kong), abstracting data from eligible patients (NCT05207423).
J Oral Rehabil
January 2025
Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Gazi University, Ankara, Turkey.
Background: Surface electromyography (sEMG) has been used in a wide range of studies conducted in the field of dysphagia.
Objectives: The main aim of this case-control study is to obtain how submental and infrahyoid sEMG signals differ based on residue, penetration and aspiration.
Methods: A total of 100 participants (50 patients with suspected dysphagia and 50 healthy controls) were enrolled in the present study.
Ann Clin Transl Neurol
January 2025
NEUROFARBA Department, Neurosciences Section, University of Florence, Florence, Italy.
Objectives: We aim to investigate cognitive phenotype distribution and MRI correlates across pediatric-, elderly-, and adult-onset MS patients as a function of disease duration.
Methods: In this cross-sectional study, we enrolled 1262 MS patients and 238 healthy controls, with neurological and cognitive assessments. A subset of 222 MS patients and 92 controls underwent 3T-MRI scan for brain atrophy and lesion analysis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!